Compare RCUS & HUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCUS | HUN |
|---|---|---|
| Founded | 2015 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.4B |
| IPO Year | 2018 | 2004 |
| Metric | RCUS | HUN |
|---|---|---|
| Price | $26.12 | $13.69 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 11 |
| Target Price | ★ $30.27 | $12.09 |
| AVG Volume (30 Days) | 999.3K | ★ 5.0M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.55% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $247,000,000.00 | ★ $5,683,000,000.00 |
| Revenue This Year | N/A | $3.08 |
| Revenue Next Year | $45.62 | $5.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.06 | $7.30 |
| 52 Week High | $26.40 | $14.38 |
| Indicator | RCUS | HUN |
|---|---|---|
| Relative Strength Index (RSI) | 65.38 | 57.26 |
| Support Level | $19.62 | $10.41 |
| Resistance Level | N/A | $14.30 |
| Average True Range (ATR) | 1.56 | 0.64 |
| MACD | 0.30 | 0.01 |
| Stochastic Oscillator | 69.54 | 73.38 |
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. The product portfolio of the company comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, and others. Its operating segments are Polyurethanes, Performance Products, and Advanced Materials. The company derives the majority of its revenue from the Polyurethanes segment, which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.